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Stem Cell Transplantation
The origin of epithelial neoplasms after allogeneic
stem cell transplantation
We analyzed five women, who have developed
epithelial neoplasms after sex-mismatched stem
cell transplants. Using in situ hybridization for sex
chromosome-specific DNA probes and immuno-
histochemistry we identified the origin of the
tumor cells. We conclude that none of the non-
hematologic malignancies was of donor origin. 
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Besides hematopoietic stem cells, bone marrow con-
tains mesenchymal stem cells that differentiate into
mature cells of mesenchymal tissues such as muscle,
bone, and cartilage. Over the years bone marrow-derived
stem cells have become of great interest for researchers,
mainly beacuse of the high degree of plasticity of these
cells.1 It has been suggested that bone marrow-derived
cells are frequently recruited to sites of tissue injury to
replace damaged cells. Whether tissue injury is necessary
to recruit stem cells remains unclear. The existing theory
about the stem cell origin of tissues has led to a closely
related theory that cancer could also be of stem cell ori-
gin, as reviewed by Sell.2 Whether bone marrow-derived
cells could actually be a potential source of malignancy,
was recently investigated.3 Using the Helicobacter
felis/C57BL/6 mouse model for gastric cancer, in which
mice are irradiated before infection and transplanted
with bone marrow cells that bear a genetically engi-
neered marker to distinguish donor cells from recipient
cells, they showed that chronic Helicobacter infection
induces repopulation of the stomach with bone marrow
derived cells and that these cells eventually progress into
intra-epithelial cancer. These findings led us to question
whether non-hematologic malignancies that have devel-
oped in patients after stem cell transplantation (SCT) are
of donor origin. We analyzed tumor tissues from five
women, who had been transplanted with T-cell depleted
marrow from an HLA-identical brother, and who had
developed non-hematologic neoplasia without severe
chronic graft-versus-host disease (Table 1). Clinical data
and the patients’ material were obtained from the
archives of the Departments of Haematology and
Pathology of Radboud University Nijmegen Medical
Centre. In total 150 women have undergone sex-mis-
matched SCT, and the incidence of secondary malignan-
cies in this group was similar to that in the group receiv-
ing gender-matched grafts. The number and type of sec-
ondary malignancies that occurred in our series were in
line with those reported in the literature.4
We combined immunohistochemistry and in situ
hybridization (ISH) to analyze the origin of the tumor
cells. To identify tumor cells, tissue sections were incu-
bated with monoclonal antibody against CAM5.2 and
power-alkaline phosphatase, respectively. Visualization
was then performed with 4-nitro blue tetrazolium chlo-
ride (NBT)-5-bromo-4-chloro-3-indolyl phosphate (BCIP)
solution. For ISH the satellite III DNA probe for chromo-
some Y (DYZ1) was used to identify the presence of
donor cells in the tumors of transplant recipients. Probe
and target DNA were denaturated and hybridization was
performed overnight at 37°C. The probe was detected by
mouse anti-biotin (Dako, Glostrup, Denmark), biotin-
labeled horse anti-mouse, and avidin-biotin-labeled per-
oxidase complex (Vectastain Elite ABC Kit, Vector
Laboratories Inc., Burlingame, CA, USA). Visualization of
the DNA probe was performed with 0.5 mg/mL 3,3-
diaminobenzidine tetra hydrochloride. Slides were coun-
terstained with nuclear fast red, dehydrated. Prior to the
previously described double staining, ISH was performed
for chromosomes Y and X. 
The analyzed lesions developed between 1.5 and 10
years after transplantation, and consisted of pre-malig-
nant and fully developed cancers of various grades of
malignancy. In all cases donor inflammatory cells, main-
ly lymphocytes (based on morphology), were present, as
expected. However, all five (pre)-neoplasms were of
recipient origin since in all cases the tumor cells did not
contain chromosome Y (Figure 1). In addition, the tumor
cells showed diploidy and polyploidy (in two patients
with a ductal carcinoma in situ) for chromosome X (data
not shown). In agreement with previous research,5 our
data demonstrate the presence of bone marrow derived
Table 1. Female patients with non-hematological malignancies after sex-mismatched stem cell transplantation (SCT). 
Patient’s Patient’s Indication for Donor-type2 Conditioning CD3+ cells left GVHD Interval Histological
sex age SCT1 for SCT3 in the graft acute/chronic4 SCT-diagnosis diagnosis
at SCT (×106/kg) carcinoma (years)
F 47 NHL HLA-id TBI plus CPM 0.74 0/0 1.5 Moderately differentiated invasive 
ductal carcinoma
F 52 MM HLA-id Ida plus TBI 0.74 I / L 5 Well differentiated invasive
plus CPM ductal carcinoma
F 51 RAEB-t HLA-id Ida plus TBI 0.72 I / 0 8.5 Poorly differentiated ductal
plus CPM carcinoma in situ
F 56 MM HLA-id TBI plus CPM 0.72 II / 0 3 Basocellular carcinoma
F 54 RA HLA-id Ida plus TBI 0.70 I / L 10 Lobular carcinoma in situ
plus CPM
1NHL: Non-Hodgkin’s lymphoma; MM: multiple myeloma; RAEB-t : refractory anemia with an excess of blasts in transformation; RA: refractory anemia; 2HLA-id:
HLA-identical brother: 3TBI: total body irradiation 9 Gy; CPM: cyclophosphamide 120 mg/kg; Ida: idarubicin 42 mg/m2; 4L chronic GVHD: limited chronic
graft-versus-host disease.
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endothelial cells. The endothelium within the tumor
showed mixed chimerism, which is at least partially the
result of neo-angiogenesis. In contrast, other studies have
repeatedly shown that post-transplant lymphoprolifera-
tive disorders after SCT are mostly derived from donor
cells.6,7 This was expected since SCT can fully replace the
hematopoietic system, including lymphopoiesis. Solid
tumors arise after SCT even more often,8 but until now
studies into the origin of the tumor cells have not been
reported.
The present findings show that none of the epithelial
malignancies after SCT was of donor origin. This is in
contrast with the experimental model of Houghton and
Wang.3 The major difference is that the Helicobacter-asso-
ciated gastric cancer in their model arises after continued
inflammation and tissue repair. The tumors we describe
are not related to chronic inflammation and no such cases
were present in our relatively large series with a median
follow-up of 10 years. Of course we cannot exclude the
rare occurrence of donor-derived cancers, but the mecha-
nism by which most transplantation-associated cancers
arise might be different from that in an experimental
model. We conclude that the investigated non-hemato-
logic malignancies are derived from recipient rather than
donor epithelial cells.
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Figure 1. Invasive ductal carcinoma without bone marrow-derived
tumor cells. Immunohistochemical staining of tumor tissue for
CAM 5.2 (purple) with in situ hybridization for Y chromosome-spe-
cific DNA probe (brown dots), counterstained by nuclear fast red.
The tumor sample was taken from a 48-years/old female patient,
1.5 years after a stem cell transplant. Y chromosome positive
cells were present, but no double positivity for both CAM 5.2 and
Y chromosome was detected. Magnification is 200x, and 400x
(insert).
